Sign up to save your podcasts
Or
Share Oxylipin metabolism is controlled by mitochondrial b-oxidation during bacterial inflammation.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Oxylipin metabolism is controlled by mitochondrial b-oxidation during bacterial inflammation.
Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.08.17.252007v1?rss=1
Authors: Misheva, M., Kotzamanis, K., Davies, L., Tyrrell, V., Rodrigues, P., Benavides, G., Christine, H., Murphy, R., Kennedy, P., Taylor, P., Rosas, M., Jones, S., Deshpande, S., Andrews, R., Czubala, M., Gurney, M., Aldrovandi, M., Meckelmann, S., Ghazal, P., Darley-Usmar, V., White, D., O'Donnell, V.
Abstract:
Oxylipins are potent mediators requiring strict control. How they are removed en masse during infection/inflammation is unknown. Herein, lipopolysaccharide (LPS) dynamically increased their mitochondrial b-oxidation, impacting leukocyte bioactivity. Genetic/pharmacological targeting of CPT1 showed <50 oxylipins were robustly removed by macrophage mitochondria during inflammation in vitro and in vivo. Stable isotope-lipidomics demonstrated secretion-reuptake recycling for 12-HETE and its intermediate metabolites. Oxylipin b-oxidation was uncoupled from oxidative phosphorylation. Transcriptional interrogation of human neonatal sepsis revealed significant upregulation of many candidates, encoding proteins for mitochondrial uptake and b- oxidation of long-chain fatty acyls (ACSL1,3,4, ACADVL, CPT1B, CPT2, HADHB). ACSL1/Acsl1 upregulation was a signature in multiple human/murine macrophage datasets. In summary, mitochondrial b-oxidation is a regulatory metabolic checkpoint for oxylipins during infection. This has implications for patients with CPT1 deficiency, at higher risk of mortality during respiratory infections. We propose that mitochondrial b-oxidation capacity to remove oxylipins during infection may directly influence development of inflammation.
Copy rights belong to original authors. Visit the link for more info
View all episodes
By Multimodal LLCLink to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.08.17.252007v1?rss=1
Authors: Misheva, M., Kotzamanis, K., Davies, L., Tyrrell, V., Rodrigues, P., Benavides, G., Christine, H., Murphy, R., Kennedy, P., Taylor, P., Rosas, M., Jones, S., Deshpande, S., Andrews, R., Czubala, M., Gurney, M., Aldrovandi, M., Meckelmann, S., Ghazal, P., Darley-Usmar, V., White, D., O'Donnell, V.
Abstract:
Oxylipins are potent mediators requiring strict control. How they are removed en masse during infection/inflammation is unknown. Herein, lipopolysaccharide (LPS) dynamically increased their mitochondrial b-oxidation, impacting leukocyte bioactivity. Genetic/pharmacological targeting of CPT1 showed <50 oxylipins were robustly removed by macrophage mitochondria during inflammation in vitro and in vivo. Stable isotope-lipidomics demonstrated secretion-reuptake recycling for 12-HETE and its intermediate metabolites. Oxylipin b-oxidation was uncoupled from oxidative phosphorylation. Transcriptional interrogation of human neonatal sepsis revealed significant upregulation of many candidates, encoding proteins for mitochondrial uptake and b- oxidation of long-chain fatty acyls (ACSL1,3,4, ACADVL, CPT1B, CPT2, HADHB). ACSL1/Acsl1 upregulation was a signature in multiple human/murine macrophage datasets. In summary, mitochondrial b-oxidation is a regulatory metabolic checkpoint for oxylipins during infection. This has implications for patients with CPT1 deficiency, at higher risk of mortality during respiratory infections. We propose that mitochondrial b-oxidation capacity to remove oxylipins during infection may directly influence development of inflammation.
Copy rights belong to original authors. Visit the link for more info